Back to top
more

Roche Holding (RHHBY)

(Delayed Data from OTC)

$41.71 USD

41.71
3,332,734

+0.28 (0.68%)

Updated Aug 23, 2024 04:00 PM ET

Zacks Rank:

This is our short term rating system that serves as a timeliness indicator for stocks over the next 1 to 3 months. How good is it? See rankings and related performance below.

Zacks Rank Definition Annualized Return
1Strong Buy23.68%
2Buy17.55%
3Hold9.21%
4Sell4.93%
5Strong Sell2.36%
S&P50010.96%

Zacks Rank Education - Learn about the Zacks Rank

Zacks Rank Home - Zacks Rank resources in one place

Zacks Premium - The only way to fully access the Zacks Rank

1-Strong Buy of 5 1        

Style Scores:

The Style Scores are a complementary set of indicators to use alongside the Zacks Rank. It allows the user to better focus on the stocks that are the best fit for his or her personal trading style.

The scores are based on the trading styles of Value, Growth, and Momentum. There's also a VGM Score ('V' for Value, 'G' for Growth and 'M' for Momentum), which combines the weighted average of the individual style scores into one score.

Value Score A
Growth Score A
Momentum Score A
VGM Score A

Within each Score, stocks are graded into five groups: A, B, C, D and F. As you might remember from your school days, an A, is better than a B; a B is better than a C; a C is better than a D; and a D is better than an F.

As an investor, you want to buy stocks with the highest probability of success. That means you want to buy stocks with a Zacks Rank #1 or #2, Strong Buy or Buy, which also has a Score of an A or a B in your personal trading style.

Zacks Style Scores Education - Learn more about the Zacks Style Scores

C Value C Growth C Momentum C VGM

Industry Rank:

The Zacks Industry Rank assigns a rating to each of the 265 X (Expanded) Industries based on their average Zacks Rank.

An industry with a larger percentage of Zacks Rank #1's and #2's will have a better average Zacks Rank than one with a larger percentage of Zacks Rank #4's and #5's.

The industry with the best average Zacks Rank would be considered the top industry (1 out of 265), which would place it in the top 1% of Zacks Ranked Industries. The industry with the worst average Zacks Rank (265 out of 265) would place in the bottom 1%.

Zacks Rank Education -- Learn more about the Zacks Rank
Zacks Industry Rank Education -- Learn more about the Zacks Industry Rank

Top 36% (90 out of 250)

Industry: Large Cap Pharmaceuticals

Better trading starts here.

Zacks News

Arpita Dutt headshot

5 Drug Stocks in Focus on World MS Day

Life with MS -- this world MS day, here's a look at 5 stocks including Biogen (BIIB) that are key players in the multiple sclerosis (MS) market.

    Kite Pharma Cancer Drug BLA Gets Priority Review Status

    Kite Pharma, Inc. (KITE) announced that its biologics license application (BLA) for its experimental CAR-T therapy, axicabtagene ciloleucel has been accepted for priority review by the FDA.

      Roche (RHHBY) Presents Positive Data on IPF Drug Esbriet

      Roche Holding AG (RHHBY) announced new retrospective data analyses for idiopathic pulmonary fibrosis (IPF) drug, Esbriet.

        Puma Soaring After Neratinib FDA Panel Win, Time to Buy?

        Shares of Puma Biotechnology, Inc. (PBYI) have risen 35% since it announced that an FDA advisory committee recommended the approval of its lead pipeline candidate, neratinib for the treatment of some breast cancers.

          Alnylam Pharmaceuticals (ALNY) Progressing Well on Pipeline

          We issued an updated research report on Alnylam Pharmaceuticals, Inc. (ALNY) on May 23, 2017.

            BioLineRx Makes Regulatory Submission for Trial of BL-8040

            BioLineRx Ltd. (BLRX) announced that it has submitted a regulatory filing required to start a phase Ib study for BL-8040 in combination with Roche Group's (RHHBY) Tecentriq (atezolizumab).

              Roche's Arthritis Drug Gets FDA Nod for Label Expansion

              Roche Holdings AG (RHHBY) announced that the FDA has approved Actemra subcutaneous injection for the treatment of giant cell arteritis (GCA).

                Sanofi/Regeneron's Kevzara Gets FDA Approval for Arthritis

                Sanofi (SNY) and partner Regeneron Pharmaceuticals, Inc. (REGN) announced that the FDA has approved their pipeline candidate sarilumab to be marketed under the trade name of Kevzara.

                  Clovis' (CLVS) PARP Inhibtor Shows Promise, Risks Remain

                  On May 19, we issued an updated research report on Boulder, CO based Clovis Oncology, Inc. (CLVS).

                    Merck KGaA (MKGAF) Q1 Earnings Fall Y/Y, Revenues Increase

                    Merck KGaA (MKGAF) reported first-quarter 2017 earnings of $1.28 per American Depositary Share, 14.7% lower than the year-ago figure of $1.50.

                      Immune Design (IMDZ) Posts Narrower-than-Expected Loss in Q1

                      Immune Design Corp. (IMDZ) reported first-quarter 2017 loss of 50 cents per share, narrower than the Zacks Consensus Estimate of a loss of 62 cents and also a year-ago loss of 61 cents.

                        AstraZeneca Imfinzi Positive in Phase III Lung Cancer Study

                        AstraZeneca PLC (AZN) recently announced positive data from a phase III PACIFIC study evaluating its oncology candidate, Imfinzi (durvalumab).

                          Arpita Dutt headshot

                          Pharma Stock Roundup: Mylan, Teva Q1 Earnings, Roche Drug Misses in Pivotal Study

                          While companies like Mylan (MYL), Allergan and Teva reported Q1 results this week, several companies provided updates on their cancer drugs.

                            Inovio (INO) Q1 Loss Narrower Than Expected, Revenues Beat

                            Inovio Pharmaceuticals, Inc. (INO) reported loss of 31 cents for the first quarter of 2017, narrower than the Zacks Consensus Estimate of a loss of 34 cents.

                              Puma (PBYI) Q1 Loss Narrows, Focus Remains on Neratinib

                              Puma Biotechnology, Inc. (PBYI) reported a first-quarter 2017 loss of $1.97 per share, narrower than the Zacks Consensus Estimate of a loss of $2.08 and the year-ago loss of $2.19.

                                Prothena (PRTA) Q1 Loss Narrower than Expected, Updates View

                                Prothena Corporation plc (PRTA) reported a loss of 99 cents per share in the first quarter of 2017, wider than the year-ago loss of 81 cents.

                                  Mylan (MYL) Beats on Q1 Earnings, Revenues Miss Estimates

                                  Mylan's (MYL) first-quarter results beat on earnings but missed the top line due to a decline in EpiPen sales.

                                    Allergan (AGN) Beats Q1 Earnings Estimates, Ups 2017 View

                                    Allergan plc's (AGN) first-quarter 2017 earnings came in at $3.35 per share, beating the Zacks Consensus Estimate of $3.32 by 0.9%.

                                      Epizyme (EPZM) Incurs Narrower-than-Expected Loss in Q1

                                      Epizyme, Inc. (EPZM) reported a loss of 56 cents per share in the first quarter of 2017, narrower than the Zacks Consensus Estimate of loss of 63 cents but wider than the year-ago loss of 41 cents.

                                        The Zacks Analyst Blog Highlights: Arcelor Mittal, Roche Holding AG and Cummins

                                        The Zacks Analyst Blog Highlights: Arcelor Mittal, Roche Holding AG and Cummins

                                          Kite Pharma (KITE) Posts Q1 Loss, Reveals CAR-T Patient Death

                                          Kite Pharma, Inc. (KITE) reported wider-than-expected loss in the first quarter of 2017.

                                            John Blank headshot

                                            The European Union Got Stronger: Global Week Ahead

                                            This Global Week Ahead started with a foregone conclusion: Emmanuel Macron is the new French president. Imagine the sighs of relief. However, it was a 'sell the news' trading event.

                                              What's in Store for Immune Design (IMDZ) Stock in Q1 Earnings?

                                              Immune Design Corp (IMDZ) is expected to report first-quarter 2017 results on May 9.

                                                Ophthotech (OPHT) Q1 Loss Narrower than Expected, Sales Miss

                                                Ophthotech Corporation (OPHT) reported first-quarter 2017 loss of $1.20 per share, narrower than the Zacks Consensus Estimate of a loss of $1.31 but wider than the year-ago loss of $1.03

                                                  Clovis (CLVS) Q1 Loss Narrows, Rubraca Off to a Good Start

                                                  Clovis Oncology, Inc. (CLVS) reported first-quarter 2017 loss of $1.33 per share, which was narrower than the Zacks Consensus Estimate of a loss of $1.43 as well as the year-ago loss of $2.17 per share.